Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/TpidkSO7tDg/3Ryb
Thursday, February 24, 2011
Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine Shows Promise In Clinical Trial Conducted At University Of Pittsburgh
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs. Developed by Dr...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment